Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
22058086
Public Release Type:
Journal
Publication Year: 2012
Affiliation: University of Pennsylvania, Philadelphia, PA, USA. rajender.reddy@uphs.upenn.edu
DOI:
https://doi.org/10.1177/1740774511427064
Authors:
Miller C,
Afdhal N,
Navarro VJ,
Hawke RL,
Wahed AS,
Doo E,
Meyers CM,
SyNCH Study Group,
Afdhal N,
Colagreco J,
Thomas NP,
Gupta D,
Navarro V,
Verma M,
Borg E,
Davis P,
Fried M,
Hawke R,
Howell M,
Soule T,
Kaplan DE,
Kennedy C,
Micheli A,
Reddy K,
Wirjosemito A,
Belle S,
Bowen J,
Kurs-Lasky M,
Lawlor S,
Wahed A,
Zadorozny E,
Duffy L,
Meyers C,
Doo E,
Hoofnagle J,
Seeff L,
D'Amato M,
Rovati L,
Reddy KR,
Belle SH,
Fried MW
Studies:
Silymarin Trial for Hepatitis C and NASH
Chronic hepatitis C is associated with significant morbidity and mortality as a consequence of progression to cirrhosis, hepatocellular carcinoma, and liver failure. Current treatment for chronic hepatitis C with pegylated interferon (IFN) and ribavirin is associated with suboptimal responses and numerous adverse effects. A number of botanical products have been used to treat hepatic disorders. Silymarin, extracted from the milk thistle plant, Silybum marianum (L) Gaertn. (Asteraceae), has been most widely used for various liver disorders, including chronic hepatitis C, B, and alcoholic liver disease. However, the safety and efficacy of silymarin have not been studied systematically in chronic hepatitis C.
